Novo, Nordisk

Novo Nordisk Trims New Jersey Footprint While Buybacks and Pipeline Wins Pile Up

Published on 11/20/2026 at 16:50 | Editorial boerse-global.de
Novo Nordisk plans 215 more layoffs at its New Jersey HQ from February 2027, as buybacks reach DKK 12.1 billion and Wegovy pill sales gain traction.
Novo, Nordisk, Trims, New, Jersey, Footprint, While, Buybacks, Pipeline, Wins Illustration mit AI erstellt.

Novo Nordisk will cut another 215 jobs at its U.S. headquarters in Plainsboro, New Jersey, with the reductions set to take effect from February 2027, according to a filing with the state's labor department reported by NJBIZ. The move extends a cost drive that has already reshaped the company's global workforce.

The Plainsboro reductions build on a round of layoffs announced in September. CEO Mike Doustdar has pushed back at the suggestion that Novo Nordisk is proceeding slice by slice, dismissing the "salami" tag applied to its approach. For investors, the more pertinent question is how much the cuts actually contribute to the company's savings target — and the headline headcount alone does not answer it.

Roughly 13,000 employees have already left as part of the worldwide restructuring, per NJBIZ. Novo Nordisk is chasing annual savings of USD 1.3 billion by the end of 2026, a goal tied to the overhaul as a whole rather than to the U.S. headquarters specifically. The New Jersey cuts, notably, will not land until after that company-wide deadline has passed.

Buyback tally reaches DKK 12.1 billion

Alongside the restructuring, the Danish drugmaker has been steadily retiring its own stock. On Monday it disclosed the repurchase of 1.13 million B-shares for about DKK 310 million. Since February 4, it has bought back some 43.7 million B-shares for roughly DKK 12.1 billion in total.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

On the commercial front, the tablet version of Wegovy is starting to pull its weight. The pill launched in the U.S. in January 2026 and is already making a measurable contribution to sales, well before Novo Nordisk rolls it out elsewhere. The company intends to take the oral formulation to more than 20 countries by mid-2027, a timeline that hinges on available manufacturing capacity and the necessary approvals.

That momentum fed into guidance. In early November, after better-than-expected quarterly results, Novo Nordisk lifted its full-year 2026 outlook for the third time. Revenue and operating profit are now each expected to land anywhere between a 2% decline and 2% growth — an improved range that still leaves room for a contraction.

EU green light for FREHEMGO

Regulators in Europe added another string to the pipeline. On November 13, the European Commission granted marketing authorization for FREHEMGO as routine prophylaxis in haemophilia A, covering adults and children with or without inhibitors. Novo Nordisk expects the first European launches next year.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Clinical data also drew attention. On November 14, the company reported phase 3 results from the REDEFINE 9 trial of CagriSema, estimating mean weight loss of 20.7% and 21.0% in the two lower-dose arms, against 2.0% for placebo. Those estimates are for week 68 and assume participants stayed on treatment.

A post-hoc analysis of the REDEFINE 1 study, published on the Sunday, found that 67.8% of patients treated with CagriSema responded early to the therapy. Within that group, observed weight loss through week 68 averaged 25.4%. The retrospective analysis is intended to generate hypotheses rather than confirm them.

Ad

Novo Nordisk Stock: New Analysis - 20 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70540499 |